A carbapenem antibiotic and preparation method thereof
By using a single solvent water and a palladium carbon catalyst in the preparation of carbapenem antibiotics, the problem of solvent systems in the prior art was solved, and the preparation of high-purity and low-toxic carbapenem antibiotics was achieved, with broad-spectrum antibacterial Active and long-lasting, suitable for industrial production.
Patent Information
- Application Number
- CN202411280631.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-13
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-09-13
AI Technical Summary
In the existing preparation methods for carbapenem antibiotics, the solvent system has problems such as catalyst dissolution, metal complex formation, degradation and environmental pollution, which limits its clinical application and industrial production.
A single solvent water is used as the reaction medium, and hydrogenation reaction is carried out through a palladium-carbon catalyst to prepare carbapenem antibiotics, avoiding the use of solvents and subsequent treatment steps, and improving product purity and production efficiency.
The preparation of high-purity and low-toxic carbapenem antibiotics has been achieved, with broad-spectrum antibacterial activity and long-term effectiveness, is suitable for industrial large-scale production, and reduces the heavy metal content and environmental impact.
Smart Images

Figure CN118791495B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a carbapenem antibiotic and a preparation method thereof. Background Art
[0002] Carbapenem antibiotics are a class of β-lactam antibiotics developed in the 1970s. They have attracted much attention because of their broad antibacterial spectrum, strong antibacterial activity, and stability to β-lactamase. Its structural characteristics are that the sulfur at the 1st position of the penicillin parent nucleus is replaced by carbon, and the 2nd position has a double bond, which combines the five-membered ring of penicillin and the conjugated double bond of cephalosporin to activate the β-lactam ring. Currently, the drugs of this type that have been marketed include imipenem, meropenem, doripenem, biapenem, ertapenem, etc. However, with the increase in the frequency of clinical use, drug resistance has gradually been shown. Due to the increasing bacterial resistance caused by the abuse of antibiotics, and due to the limitations of digestive tract absorption, the currently marketed carbapenems can only be administered as injections in clinical practice, with low clinical utilization, and except for ertapenem, the half-life is short, which can no longer meet clinical needs. Therefore, it is urgent to research and develop carbapenem antibiotics with good antibacterial activity, including drug-resistant bacteria, and good chemical stability and DHP-I stability. The prior art generally prepares carbapenem antibiotics by removing the protecting group through the hydrogenation reaction of penicillin in the presence of a certain solvent system. The solvent system used in the prior art generally includes a buffer solution and / or an organic solvent. The problems with the solvent system are: (1) the prior solvent system will cause the catalyst to dissolve and easily generate metal complexes, resulting in excessive heavy metal content in the product; (2) the prior solvent system using a buffer will produce a large amount of degradation products. After the reaction is completed, the buffer and other impurities need to be removed, and column chromatography separation is required. The post-processing is cumbersome and not conducive to large-scale production; (3) the prior solvent system using an organic solvent is subject to the increasingly stringent environmental protection laws and regulations. Summary of the invention
[0003] In view of the deficiencies in the prior art, the present invention provides a carbapenem antibiotic and a preparation method thereof.
[0004] The present invention is achieved through the following technical solutions:
[0005] A carbapenem antibiotic, comprising a compound represented by formula 1 or a pharmaceutically acceptable salt, a hydrate, an isomer or a hydrate of a salt thereof:
[0006] Formula 1;
[0007] wherein R1 represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxyl group, an amino group, a nitro group, a cyano group, a C1-C4 alkyl group which is substituted or unsubstituted by a halogen atom, a hydroxyl group, a carboxyl group, an amino group, a nitro group or a cyano group;
[0008] R2 represents a hydrogen atom, a fluorine atom, a hydroxyl group, a carboxyl group, an amino group, a trifluoromethyl group, a sulfonic acid group, an aminosulfonyl group, a carbamoyl group or a C1-C4 alkyl group.
[0009] Furthermore, the halogen atom is a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
[0010] Furthermore, the compound is preferably a compound having the structural formula shown in Formula 2:
[0011] Formula 2.
[0012] The present invention also provides a method for preparing the carbapenem antibiotic, and the reaction equation is as follows:
[0013] ;
[0014] Furthermore, the preparation method of the palladium-carbon catalyst comprises the following steps:
[0015] (1) Activated carbon was placed in a muffle furnace, activated at 550°C for 5 h, mixed with glycine, triethylamine and water, heated at 100°C for 5 h, filtered, the residue was washed with sodium carbonate solution, and dried at 130°C to obtain modified carbon;
[0016] (2) dissolving palladium chloride in anhydrous ethanol to form a palladium alcohol solution, adding the modified carbon obtained in step (1) to the palladium alcohol solution, ultrasonicating at 50 kHz for 1-2 h, filtering with suction, washing the filter cake with distilled water and drying at 110° C. to obtain a palladium-carbon catalyst.
[0017] Furthermore, in step (1), the ratio of activated carbon, glycine, triethylamine and water is 0.1 g: 0.4 mmol: 0.2 g: 20 g.
[0018] Furthermore, the ratio of palladium chloride to anhydrous ethanol in step (2) is 20 g:1 L.
[0019] Furthermore, the ratio of the palladium alcohol solution to the modified carbon in step (2) is 15 mL:1 g.
[0020] Furthermore, the method for preparing the carbapenem antibiotic comprises the following steps:
[0021] S1: Preparation of intermediate (I): Add (2S, 4S)-4-acetylthio-2-carboxy-1-(tert-butyloxycarbonyl)pyrrolidine (i.e., raw material 1) and anhydrous tetrahydrofuran to a dry reaction bottle; under nitrogen protection, add 1,1-carbonyldiimidazole (i.e., CDI) at room temperature for reaction, add an acetone solution of raw material 2, and continue the reaction; then add 1 mol / L hydrochloric acid dropwise, extract with ethyl acetate, wash the organic phase with water and saturated sodium chloride solution in turn, concentrate to dryness under reduced pressure, and recrystallize with a mixed solution of acetonitrile-cyclohexane to obtain intermediate (I);
[0022] S2: Preparation of intermediate (II): Add a dichloromethane solution of intermediate (I) to a reaction flask, cool to 2-4°C in an ice bath, add triethylamine, stir for 5 min, then dropwise add a dichloromethane solution of (Boc)2O; stir for 1 h, add distilled water under ice cooling, separate the aqueous layer, extract the aqueous layer with dichloromethane, combine the organic layers, dry over anhydrous sodium sulfate, concentrate to dryness, add 5 mol / L hydrochloric acid, stir for 2 h, adjust to pH 7.8-8.2 with 1 mol / L NaOH solution, precipitate a solid, and recrystallize with a mixed solution of acetonitrile and acetone to obtain intermediate (II);
[0023] S3: Preparation of intermediate (III): Add an acetonitrile solution of (4R,5S,6S)-3-diphenyloxyphosphoryloxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3,2,0]hept-2-ene-2-carboxylic acid p-nitrobenzyl ester (i.e., raw material 3) to a reaction flask, cool to -10°C, add diisopropylethylamine and an acetonitrile solution of intermediate (II), and stir at 0°C for 15 h; after the reaction is completed, dilute with ethyl acetate, wash with water and saturated brine in turn, and dry and concentrate the organic layer to obtain intermediate (III);
[0024] S4: Preparation of compound (IV): Deionized water, intermediate III, 2,6-lutidine and palladium-carbon catalyst were added to a hydrogenation reaction kettle in sequence; hydrogen was introduced until the pressure in the kettle reached 1.5 MPa, the temperature was controlled at 25°C, and stirring was performed for 2 h; stirring was stopped, hydrogen was discharged, replaced with nitrogen, filtered, acetone was added to the filtrate, stirred and crystallized at 0°C for 4 h, filtered, and the obtained solid was dried in vacuo to obtain compound (IV).
[0025] Furthermore, in step S1, the usage ratio of raw material 1, anhydrous tetrahydrofuran, CDI, raw material 2 and hydrochloric acid is 1 mmol:4 mL:1.2 mmol:1.2 mmol:2 mL.
[0026] Furthermore, in the acetone solution of raw material 2 in step S1, the dosage ratio of raw material 2 to acetone is 1 mmol:1 mL.
[0027] Furthermore, the volume ratio of acetonitrile to cyclohexane in the acetonitrile-cyclohexane mixed solution in step S1 is 1:1.
[0028] Furthermore, in the dichloromethane solution of the intermediate (I) in step S2, the ratio of the intermediate (I) to dichloromethane is 1 mmol:2 mL.
[0029] Furthermore, the volume ratio of the triethylamine in step S2 to the dichloromethane solution of the intermediate (I) is 1:8.
[0030] Furthermore, the ratio of (Boc)2O to dichloromethane in the dichloromethane solution of (Boc)2O in step S2 is 1 g:5 mL.
[0031] Furthermore, the volume ratio of the dichloromethane solution of (Boc)2O to triethylamine in step S2 is 10:1.
[0032] Furthermore, the volume ratio of distilled water to triethylamine in step S2 is 10:1.
[0033] Furthermore, the volume ratio of hydrochloric acid to triethylamine in step S2 is 20:1.
[0034] Furthermore, the volume ratio of acetonitrile to acetone in the acetonitrile and acetone mixed solution in step S2 is 1:1.
[0035] Furthermore, the ratio of raw material 3 to acetonitrile in the acetonitrile solution of raw material 3 in step S3 is 1 mmol:5 mL.
[0036] Furthermore, in the acetonitrile solution of diisopropylethylamine and intermediate (II) in step S3, the amount ratio of diisopropylethylamine, intermediate (II) and acetonitrile is 8 mL:31 mmol:92 mL.
[0037] Furthermore, the volume ratio of the acetonitrile solution of diisopropylethylamine and intermediate (II) in step S3 to the acetonitrile solution of raw material 3 is 1:1.5.
[0038] Furthermore, the volume ratio of the ethyl acetate in step S3 to the acetonitrile solution of raw material 3 is 8:3.
[0039] Furthermore, in step S4, the usage ratio of deionized water to intermediate III is 40 L:1 kg.
[0040] Furthermore, the mass ratio of 2,6-lutidine, palladium-carbon catalyst and intermediate III in step S4 is 0.5:0.5:1.
[0041] Furthermore, in step S4, the volume ratio of acetone to filtrate is 4:1.
[0042] Compared with the prior art, the present invention has the following beneficial effects:
[0043] The present invention adopts a single solvent water as a reaction solvent, thereby solving the problem of the reaction solvent dissolving the catalyst, and does not require the steps of removing the organic solvent through liquid separation, extraction, reduced pressure distillation or degassing technology, and does not require the use of special reagents and equipment such as ion pair reagents and multi-stage countercurrent centrifugal extractors. After the reaction is completed and the catalyst is filtered out, purification, concentration and other steps can be directly carried out, thereby reducing product degradation and improving product purity. The invention is economical, safe, environmentally friendly and more suitable for industrial-scale operation. The compound prepared by the present invention has excellent antibacterial activity and shows low toxicity, high biosafety, broad antibacterial spectrum, and has good antibacterial activity against Gram-positive and Gram-negative, aerobic and anaerobic bacteria; it has high stability against β-lactamase and renal dehydrogenase (DHP-I), can be used for β-lactamase producing bacteria, and does not need to be used in combination with other drugs such as DHP-I inhibitors; the compound of the present invention has a long post-antibiotic effect, a long half-life in vivo, and a lasting antibacterial effect, which can reduce the number of administrations and improve the patient's tolerance; the compound of the present invention has a simple preparation process, high drug purity, high yield, and stable quality. In addition, the carbapenem antibiotic prepared by the present invention can be used in a powder-liquid double-chamber bag dosage form to further improve drug stability. The present invention performs small molecule modification on activated carbon, forms amino traction on the surface, helps the solidification of palladium ions, prevents the agglomeration of palladium ions, and achieves improved dispersibility. The catalytic activity of the prepared palladium-carbon catalyst is improved, and the product yield and purity are improved. BRIEF DESCRIPTION OF THE DRAWINGS
[0044] In order to more clearly illustrate the technical solutions in the present invention or the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings in the following description are only for the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0045] Figure 1 is the nuclear magnetic resonance spectrum of compound IV described in Example 4 of the present invention, wherein A is 1 H figure, B is 13 Figure C;
[0046] Figure 2 is a schematic diagram of the chemical structure of the compound of the present invention;
[0047] Figure 3 This is a graph showing the DHP-Ⅰ stability test results of compound IV described in Example 4-6 of the present invention;
[0048] Figure 4 This is a test chart of the antibacterial effect of compound IV described in Examples 4-6 of the present invention. DETAILED DESCRIPTION
[0049] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments, but the present invention is not limited to the following embodiments.
[0050] It should be noted that, unless otherwise specified, the chemical reagents involved in the present invention were purchased through commercial channels.
[0051] Embodiment 1: This embodiment provides a palladium carbon catalyst and a preparation method thereof, comprising the following steps:
[0052] (1) Activated carbon was placed in a muffle furnace, activated at 550°C for 5 h, mixed with glycine, triethylamine and water, and heated at 100°C for 5 h. The amount ratio of activated carbon, glycine, triethylamine and water was 0.1 g:0.4 mmol:0.2 g:20 g. The filter residue was washed with sodium carbonate solution and dried at 130°C to obtain modified carbon.
[0053] (2) dissolving palladium chloride in anhydrous ethanol to form a palladium alcohol solution, wherein the ratio of palladium chloride to anhydrous ethanol is 20 g:1 L, adding the modified carbon obtained in step (1) to the palladium alcohol solution, wherein the ratio of the palladium alcohol solution to the modified carbon is 15 mL:1 g, subjecting the mixture to ultrasonic treatment at 50 kHz for 2 h, filtering the mixture with suction, washing the filter cake with distilled water, and drying the filter cake at 110° C. to obtain a palladium-carbon catalyst.
[0054] Embodiment 2: This embodiment provides a palladium carbon catalyst and a preparation method thereof, comprising the following steps:
[0055] (1) Activated carbon was placed in a muffle furnace, activated at 550°C for 5 h, mixed with glycine, triethylamine and water, and heated at 100°C for 5 h. The amount ratio of activated carbon, glycine, triethylamine and water was 0.1 g:0.4 mmol:0.2 g:20 g. The filter residue was washed with sodium carbonate solution and dried at 130°C to obtain modified carbon.
[0056] (2) dissolving palladium chloride in anhydrous ethanol to form a palladium alcohol solution, wherein the ratio of palladium chloride to anhydrous ethanol is 20 g:1 L, adding the modified carbon obtained in step (1) to the palladium alcohol solution, wherein the ratio of the palladium alcohol solution to the modified carbon is 15 mL:1 g, subjecting the mixture to ultrasonic treatment at 50 kHz for 1 h, filtering the mixture with suction, washing the filter cake with distilled water, and drying the filter cake at 110° C. to obtain a palladium-carbon catalyst.
[0057] Embodiment 3: This embodiment provides a palladium carbon catalyst and a preparation method thereof, comprising the following steps:
[0058] (1) Activated carbon was placed in a muffle furnace, activated at 550°C for 5 h, mixed with glycine, triethylamine and water, and heated at 100°C for 5 h. The amount ratio of activated carbon, glycine, triethylamine and water was 0.1 g:0.4 mmol:0.2 g:20 g. The filter residue was washed with sodium carbonate solution and dried at 130°C to obtain modified carbon.
[0059] (2) dissolving palladium chloride in anhydrous ethanol to form a palladium alcohol solution, wherein the ratio of palladium chloride to anhydrous ethanol is 20 g:1 L, adding the modified carbon obtained in step (1) to the palladium alcohol solution, wherein the ratio of the palladium alcohol solution to the modified carbon is 15 mL:1 g, subjecting the mixture to ultrasonic treatment at 50 kHz for 1.5 h, filtering the mixture, washing the filter cake with distilled water, and drying the mixture at 110° C. to obtain a palladium-carbon catalyst.
[0060] Example 4: This example provides a compound of formula 2 and a method for preparing the same, comprising the following steps:
[0061] S1: Preparation of intermediate (I): Add (2S,4S)-4-acetylthio-2-carboxy-1-(tert-butyloxycarbonyl)pyrrolidine (raw material 1) and anhydrous tetrahydrofuran to a dry reaction flask; under nitrogen protection, add 1,1-carbonyldiimidazole (CDI) at room temperature for reaction, add 4-(2-amino-4-thiazolyl)phenol (raw material 2) in acetone solution, the ratio of raw material 2 to acetone is 1 mmol:1 mL, and continue the reaction; then add 1 mol / L hydrochloric acid dropwise, the ratio of raw material 1, anhydrous tetrahydrofuran, CDI, raw material 2 and hydrochloric acid is 1 mmol:4 mL:1.2 mmol:1.2 mmol:2 mL, extracted with ethyl acetate, the organic phase was washed with water and saturated sodium chloride solution in turn, concentrated to dryness under reduced pressure, and recrystallized with an acetonitrile-cyclohexane mixed solution, wherein the volume ratio of acetonitrile to cyclohexane in the acetonitrile-cyclohexane mixed solution was 1:1, to obtain intermediate (I);
[0062] S2: Preparation of intermediate (II): Add dichloromethane solution of intermediate (I) to a reaction flask, the amount ratio of intermediate (I) to dichloromethane is 1 mmol:2 mL, cool to 4°C in an ice bath, add triethylamine, the volume ratio of triethylamine to dichloromethane solution of intermediate (I) is 1:8, stir for 5 min, add dichloromethane solution of (Boc)2O dropwise, the amount ratio of (Boc)2O to dichloromethane is 1 g:5 mL, the volume ratio of (Boc)2O dichloromethane solution to triethylamine is 10:1, stir for 1 h, add distilled water under ice cooling, the volume ratio of distilled water to triethylamine is 10:1, separate the aqueous layer, extract the aqueous layer with dichloromethane, combine the organic layers, dry over anhydrous sodium sulfate, concentrate to dryness, add 5 mol / L hydrochloric acid, the volume ratio of hydrochloric acid to triethylamine is 20:1, stir for 2 h, and add 1 mol / L The NaOH solution was adjusted to pH 8.2 to precipitate a solid, which was recrystallized from a mixed solution of acetonitrile and acetone, with the volume ratio of acetonitrile to acetone being 1:1, to obtain intermediate (II);
[0063] S3: Preparation of intermediate (III): Add acetonitrile solution of (4R,5S,6S)-3-diphenyloxyphosphoryloxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3,2,0]hept-2-ene-2-carboxylic acid p-nitrobenzyl ester (i.e., raw material 3) into the reaction bottle, the ratio of raw material 3 to acetonitrile is 1 mmol:5 mL, cool to -10°C, add diisopropylethylamine and acetonitrile solution of intermediate (II), the ratio of diisopropylethylamine, intermediate (II) and acetonitrile is 8 mL:31 mmol:92mL, the volume ratio of the acetonitrile solution of diisopropylethylamine and intermediate (II) to the acetonitrile solution of raw material 3 is 1:1.5, and stirred at 0°C for 15h; after the reaction is completed, dilute with ethyl acetate, the volume ratio of ethyl acetate to the acetonitrile solution of raw material 3 is 8:3, wash with water and saturated brine in turn, dry and concentrate the organic layer to obtain intermediate (III);
[0064] S4: Preparation of compound (IV): deionized water, intermediate III, 2,6-lutidine and the palladium-carbon catalyst obtained in Example 1 were added to a hydrogenation reaction kettle in sequence, the amount ratio of deionized water to intermediate III was 40 L:1 kg, and the mass ratio of 2,6-lutidine, palladium-carbon catalyst and intermediate III was 0.5:0.5:1; hydrogen was introduced to the pressure in the kettle to 1.5 MPa, the temperature was controlled at 25°C, and stirred for 2 h; stirring was stopped, hydrogen was discharged, replaced with nitrogen, filtered, acetone was added to the filtrate, the volume ratio of acetone to filtrate was 4:1, stirred and crystallized at 0°C for 4 h, filtered, and the obtained solid was vacuum dried to obtain compound (IV), which is the compound shown in Formula 2, and the nuclear magnetic resonance spectrum is as shown Figure 2 shown.
[0065] Example 5: This example provides a compound of formula 2 and a method for preparing the same, comprising the following steps:
[0066] S1: Preparation of intermediate (I): Add (2S,4S)-4-acetylthio-2-carboxy-1-(tert-butyloxycarbonyl)pyrrolidine (raw material 1) and anhydrous tetrahydrofuran to a dry reaction flask; under nitrogen protection, add 1,1-carbonyldiimidazole (CDI) at room temperature for reaction, add 4-(2-amino-4-thiazolyl)phenol (raw material 2) in acetone solution, the ratio of raw material 2 to acetone is 1 mmol:1 mL, and continue the reaction; then add 1 mol / L hydrochloric acid dropwise, the ratio of raw material 1, anhydrous tetrahydrofuran, CDI, raw material 2 and hydrochloric acid is 1 mmol:4 mL:1.2 mmol:1.2 mmol:2 mL, extracted with ethyl acetate, the organic phase was washed with water and saturated sodium chloride solution in turn, concentrated to dryness under reduced pressure, and recrystallized with an acetonitrile-cyclohexane mixed solution, wherein the volume ratio of acetonitrile to cyclohexane in the acetonitrile-cyclohexane mixed solution was 1:1, to obtain intermediate (I);
[0067] S2: Preparation of intermediate (II): Add dichloromethane solution of intermediate (I) to a reaction flask, the amount ratio of intermediate (I) to dichloromethane is 1 mmol:2 mL, cool to 2°C in an ice bath, add triethylamine, the volume ratio of triethylamine to dichloromethane solution of intermediate (I) is 1:8, stir for 5 min, add dichloromethane solution of (Boc)2O dropwise, the amount ratio of (Boc)2O to dichloromethane is 1 g:5 mL, the volume ratio of (Boc)2O dichloromethane solution to triethylamine is 10:1, stir for 1 h, add distilled water under ice cooling, the volume ratio of distilled water to triethylamine is 10:1, separate the aqueous layer, extract the aqueous layer with dichloromethane, combine the organic layers, dry over anhydrous sodium sulfate, concentrate to dryness, add 5 mol / L hydrochloric acid, the volume ratio of hydrochloric acid to triethylamine is 20:1, stir for 2 h, and add 1 mol / L The NaOH solution was adjusted to pH 8.2 to precipitate a solid, which was recrystallized from a mixed solution of acetonitrile and acetone, with the volume ratio of acetonitrile to acetone being 1:1, to obtain intermediate (II);
[0068] S3: Preparation of intermediate (III): Add acetonitrile solution of (4R,5S,6S)-3-diphenyloxyphosphoryloxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3,2,0]hept-2-ene-2-carboxylic acid p-nitrobenzyl ester (i.e., raw material 3) into the reaction bottle, the ratio of raw material 3 to acetonitrile is 1 mmol:5 mL, cool to -10°C, add diisopropylethylamine and acetonitrile solution of intermediate (II), the ratio of diisopropylethylamine, intermediate (II) and acetonitrile is 8 mL:31 mmol:92mL, the volume ratio of the acetonitrile solution of diisopropylethylamine and intermediate (II) to the acetonitrile solution of raw material 3 is 1:1.5, and stirred at 0°C for 15h; after the reaction is completed, dilute with ethyl acetate, the volume ratio of ethyl acetate to the acetonitrile solution of raw material 3 is 8:3, wash with water and saturated brine in turn, dry and concentrate the organic layer to obtain intermediate (III);
[0069] S4: Preparation of compound (IV): deionized water, intermediate III, 2,6-lutidine and the palladium-carbon catalyst obtained in Example 2 were added to a hydrogenation reaction kettle in sequence, the amount ratio of deionized water to intermediate III was 40 L:1 kg, and the mass ratio of 2,6-lutidine, palladium-carbon catalyst and intermediate III was 0.5:0.5:1; hydrogen was passed until the pressure in the kettle reached 1.5 MPa, the temperature was controlled at 25°C, and stirred for 2 h; stirring was stopped, hydrogen was discharged, replaced with nitrogen, filtered, acetone was added to the filtrate, the volume ratio of acetone to filtrate was 4:1, stirred and crystallized at 0°C for 4 h, filtered, and the obtained solid was vacuum dried to obtain compound (IV), which is the compound shown in Formula 2.
[0070] Example 6: This example provides a compound of formula 2 and a preparation method thereof, comprising the following steps:
[0071] S1: Preparation of intermediate (I): Add (2S,4S)-4-acetylthio-2-carboxy-1-(tert-butyloxycarbonyl)pyrrolidine (raw material 1) and anhydrous tetrahydrofuran to a dry reaction flask; under nitrogen protection, add 1,1-carbonyldiimidazole (CDI) at room temperature for reaction, add 4-(2-amino-4-thiazolyl)phenol (raw material 2) in acetone solution, the ratio of raw material 2 to acetone is 1 mmol:1 mL, and continue the reaction; then add 1 mol / L hydrochloric acid dropwise, the ratio of raw material 1, anhydrous tetrahydrofuran, CDI, raw material 2 and hydrochloric acid is 1 mmol:4 mL:1.2 mmol:1.2 mmol:2 mL, extracted with ethyl acetate, the organic phase was washed with water and saturated sodium chloride solution in turn, concentrated to dryness under reduced pressure, and recrystallized with an acetonitrile-cyclohexane mixed solution, wherein the volume ratio of acetonitrile to cyclohexane in the acetonitrile-cyclohexane mixed solution was 1:1, to obtain intermediate (I);
[0072] S2: Preparation of intermediate (II): Add dichloromethane solution of intermediate (I) to a reaction flask, the amount ratio of intermediate (I) to dichloromethane is 1 mmol:2 mL, cool to 3°C in an ice bath, add triethylamine, the volume ratio of triethylamine to dichloromethane solution of intermediate (I) is 1:8, stir for 5 min, add dichloromethane solution of (Boc)2O dropwise, the amount ratio of (Boc)2O to dichloromethane is 1 g:5 mL, the volume ratio of (Boc)2O dichloromethane solution to triethylamine is 10:1, stir for 1 h, add distilled water under ice cooling, the volume ratio of distilled water to triethylamine is 10:1, separate the aqueous layer, extract the aqueous layer with dichloromethane, combine the organic layers, dry over anhydrous sodium sulfate, concentrate to dryness, add 5 mol / L hydrochloric acid, the volume ratio of hydrochloric acid to triethylamine is 20:1, stir for 2 h, add 1 mol / L The NaOH solution was adjusted to pH 8 to precipitate a solid, which was recrystallized from a mixed solution of acetonitrile and acetone, with the volume ratio of acetonitrile to acetone being 1:1, to obtain intermediate (II);
[0073] S3: Preparation of intermediate (III): Add acetonitrile solution of (4R,5S,6S)-3-diphenyloxyphosphoryloxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3,2,0]hept-2-ene-2-carboxylic acid p-nitrobenzyl ester (i.e., raw material 3) into the reaction bottle, the ratio of raw material 3 to acetonitrile is 1 mmol:5 mL, cool to -10°C, add diisopropylethylamine and acetonitrile solution of intermediate (II), the ratio of diisopropylethylamine, intermediate (II) and acetonitrile is 8 mL:31 mmol:92mL, the volume ratio of the acetonitrile solution of diisopropylethylamine and intermediate (II) to the acetonitrile solution of raw material 3 is 1:1.5, and stirred at 0°C for 15h; after the reaction is completed, dilute with ethyl acetate, the volume ratio of ethyl acetate to the acetonitrile solution of raw material 3 is 8:3, wash with water and saturated brine in turn, dry and concentrate the organic layer to obtain intermediate (III);
[0074] S4: Preparation of compound (IV): deionized water, intermediate III, 2,6-lutidine and the palladium-carbon catalyst obtained in Example 3 were added to a hydrogenation reaction kettle in sequence, the dosage ratio of deionized water to intermediate III was 40 L:1 kg, and the mass ratio of 2,6-lutidine, palladium-carbon catalyst and intermediate III was 0.5:0.5:1; hydrogen was passed until the pressure in the kettle reached 1.5 MPa, the temperature was controlled at 25°C, and stirred for 2 h; stirring was stopped, hydrogen was discharged, replaced with nitrogen, filtered, acetone was added to the filtrate, the volume ratio of acetone to filtrate was 4:1, stirred and crystallized at 0°C for 4 h, filtered, and the obtained solid was vacuum dried to obtain compound (IV), which is the compound shown in Formula 2.
[0075] The only difference between Comparative Example 1 and Example 1 is that activated carbon is used instead of modified carbon.
[0076] The difference between Comparative Example 2 and Example 4 is that the palladium-carbon catalyst described in Comparative Example 1 is used to replace the palladium-carbon catalyst described in Example 1.
[0077] The only difference between Comparative Example 3 and Example 4 is that the deionized water in step S4 is replaced by deionized water and tetrahydrofuran in a volume ratio of 1:1.
[0078] Experimental Example 1: Test the antibacterial activity of the compounds of the present invention: The following are clinically isolated strains, all purchased from public institutions, Gram-positive bacteria: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Enterococcus faecalis, Streptococcus pyogenes; Gram-negative bacteria: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae, Pseudomonas aeruginosa, Citrobacter freundii. Test samples: Compound IV described in Examples 4-6 of the present invention, and commercially available imipenem, meropenem for injection, and ertapenem. The agar dilution method was used, with reference to "Pharmacological Test Methodology" P1659-1660, People's Medical Publishing House, and the experimental results are shown in Tables 1-2.
[0079] Table 1 Antibacterial activity of the compounds of the present invention against Gram-positive bacteria
[0080]
[0081] Table 2 Antibacterial activity of the compounds of the present invention against Gram-negative bacteria
[0082]
[0083] The experimental results in Table 1 and Table 2 show that the MIC of Examples 4-6 groups 90 (the lowest drug concentration that inhibits 90% bacterial growth) is lower than imipenem, meropenem for injection and ertapenem, indicating that the carbapenem antibiotics of the present invention have good antibacterial activity, have strong antibacterial effects on both Gram-positive and Gram-negative bacteria, good antibacterial activity and a broad antibacterial spectrum. In addition, the compound IV obtained in Example 4-6 was placed in an environment of 40°C and 75% humidity for 6 months, and the MIC against Enterococcus faecalis and Pseudomonas aeruginosa was tested again. 90 , 0.15-0.18 μg / mL and 1.17-1.19 μg / mL, respectively, indicating that the carbapenem antibiotics of the present invention have good stability.
[0084] Experimental Example 2: Rat kidney acetone powder was suspended in 100 mL of 50 mM Tris-HCl buffer (pH 7.0) containing 20% butanol, and the suspension was stirred at 5°C for 48 h, and then the suspension was dialyzed with 50 mM Tris-HCl buffer (pH 7.0) (cellulose tube 30 / 32 Viskase Sales Corp.) until the butanol smell disappeared, thereby removing the butanol, and the dialyzate was centrifuged at 10000×g for 20 min, and the obtained supernatant was stored at -80°C. Compound IV obtained in Example 4-6 and imipenem, panipenem, and meropenem were mixed with ultrapure water, respectively, and solutions of 2 mg active ingredient / mL were prepared, and the solutions were mixed evenly with the supernatant at a volume ratio of 1:19, respectively, as the experimental group, and 50 mM Tris-HCl buffer (pH 7.0) was used to replace the supernatant, as the blank group. The reaction mixture was reacted at 37°C for 3 h to obtain a reaction mixture. The same amount of methanol as the sample reaction mixture was added under ice cooling, filtered through a 0.22 μm membrane, and the content of the effective component was detected by high performance liquid chromatography. The residual amount was calculated, and the residual amount (%) = (peak area of the experimental group / peak area of the blank group) × 100%. The results are shown in Figure 3 shown.
[0085] Figure 3 The results showed that the residual amount of compound IV obtained in Examples 4-6 was significantly higher than that of imipenem, panipenem and meropenem, indicating that compound IV of the present invention has strong renal dehydrogenase (DHP-I) stability and does not need to be used in combination with other drugs such as DHP-Ⅰ inhibitors.
[0086] Experimental Example 3: According to the CLSI broth microdilution method, 37 clinically isolated β-lactamase-producing Escherichia coli were subjected to drug sensitivity testing to determine the MIC of compound IV described in Examples 4-6 and imipenem and meropenem 50 The results are shown in Table 3.
[0087] Table 3 β-lactamase stability of the compounds of the present invention
[0088]
[0089] The results in Table 3 show that the MIC of Examples 4-6 groups 50 It is significantly lower than imipenem and meropenem, indicating that the β-lactamase-producing bacteria have a certain resistance to imipenem and meropenem, and the compound IV of the present invention has stronger antibacterial activity and high β-lactamase stability.
[0090] Experimental Example 4: Compound IV was prepared according to the method described in Examples 4-6 and Comparative Examples 2-3. The molar yield of each example and comparative example was detected. The purity of the compound was detected by HPLC, and the heavy metal content was detected. The results are shown in Table 4.
[0091] Table 4 Yield, purity and heavy metal content of compound IV
[0092]
[0093] The results in Table 4 show that the purity of Example 4-6 is higher than that of Comparative Example 2-3, the yields of Example 4-6 and Comparative Example 3 are higher than those of Comparative Example 2, and the heavy metal content of Example 4-6 is lower than that of Comparative Example 2-3, indicating that the palladium-carbon catalyst of the present invention can improve the purity and yield of the compound and reduce the heavy metal content. Although the use of an organic solvent can increase the yield, the purity decreases and the heavy metal content increases.
[0094] Experimental Example 5: 32 female Kunming white mice aged 6-8 weeks and weighing 21 g were randomly divided into 4 groups, with 8 mice in each group. 200 μL of Escherichia coli suspension (2.2×10 8 CFU) were injected into the peritoneal cavity of mice. 0.5 h after infection, the mice were given compound IV prepared in Example 4-6 and meropenem (prepared into a solution with physiological saline and injected intraperitoneally with an injection volume of 200 μL) at a dosage of 2 mg / kg body weight. The administration was continued for 3 days and the mice were observed for 5 days. The survival rate was recorded. The results are shown in Figure 4 shown.
[0095] Figure 4 The results showed that the survival rate of mice in Example 4-6 groups was significantly higher than that in the meropenem group, indicating that the compound IV of the present invention has strong antibacterial activity, low toxicity and high efficiency.
[0096] Experimental Example 6: Compound IV prepared in Example 4-6 and Comparative Example 2-3 was prepared with water for injection into a 15 mg / mL solution. 50 male SD rats were selected and randomly divided into 5 groups, each with 10 rats. They were intraperitoneally injected once a day with an injection volume of 0.1 mL / kg for 90 consecutive days. A control group was also set up to receive an equal amount of water for injection. 24 hours after the last administration, the rats were killed by cervical dislocation, and the organ coefficient (%) was calculated. Organ coefficient (%) = (organ weight / body weight) × 100%. The results are shown in Table 5.
[0097] Table 5 Organ coefficients after 90 days of administration
[0098]
[0099] The results in Table 5 show that after continuous administration for 90 days, the organ indexes of rats did not change significantly, indicating that the compound IV of the present invention has low toxicity and high biosafety.
[0100] Those skilled in the art should understand that the discussion of any of the above embodiments is merely illustrative and is not intended to imply that the scope of the present invention (including the claims) is limited to these examples. Under the concept of the present invention, the technical features in the above embodiments or different embodiments may be combined, the steps may be implemented in any order, and there are many other variations of the different aspects of the present invention as described above, which are not provided in detail for the sake of simplicity.
[0101] The present invention is intended to cover all such substitutions, modifications and variations that fall within the broad scope of the appended claims. Therefore, any omissions, modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.
Claims
1. A carbapenem antibiotic, characterized in that: The compound represented by Formula 1 or a pharmaceutically acceptable salt thereof: Formula 1; Wherein, R1 and R2 both represent hydrogen atoms.
2. The method for preparing a carbapenem antibiotic according to claim 1, characterized in that: The following steps are involved: ; S1: Preparation of intermediate (I): Add raw material 1 and anhydrous tetrahydrofuran to a dry reaction bottle; under nitrogen protection, add CDI at room temperature for reaction, add acetone solution of raw material 2, and continue the reaction; then dropwise add 1 mol / L hydrochloric acid, extract with ethyl acetate, wash the organic phase with water and saturated sodium chloride solution in turn, concentrate to dryness under reduced pressure, and recrystallize with acetonitrile-cyclohexane mixed solution to obtain intermediate (I); S2: Preparation of intermediate (II): Add a dichloromethane solution of intermediate (I) to a reaction flask, cool to 2-4°C in an ice bath, add triethylamine, stir for 5 min, then dropwise add a dichloromethane solution of (Boc)2O; stir for 1 h, add distilled water under ice cooling, separate the aqueous layer, extract the aqueous layer with dichloromethane, combine the organic layers, dry over anhydrous sodium sulfate, concentrate to dryness, add 5 mol / L hydrochloric acid, stir for 2 h, adjust to pH 7.8-8.2 with 1 mol / L NaOH solution, precipitate a solid, and recrystallize with a mixed solution of acetonitrile and acetone to obtain intermediate (II); S3: Preparation of intermediate (III): Add the acetonitrile solution of raw material 3 to the reaction flask, cool to -10°C, add diisopropylethylamine and the acetonitrile solution of intermediate (II), and stir at 0°C for 15 h; after the reaction is completed, dilute with ethyl acetate, wash with water and saturated brine in turn, dry and concentrate the organic layer to obtain intermediate (III); S4: Preparation of compound (IV): deionized water, intermediate III, 2,6-lutidine and palladium carbon catalyst were added to a hydrogenation reaction kettle in sequence; hydrogen was introduced until the pressure in the kettle reached 1.5 MPa, the temperature was controlled at 25°C, and the mixture was stirred for 2 h; stirring was stopped, hydrogen was discharged, and the mixture was replaced with nitrogen, and the mixture was filtered. Acetone was added to the filtrate, and the mixture was stirred and crystallized at 0°C for 4 h, and the mixture was filtered. The obtained solid was dried in vacuo to obtain compound (IV); The preparation method of the palladium-carbon catalyst comprises the following steps: (1) Activated carbon was placed in a muffle furnace, activated at 550°C for 5 h, mixed with glycine, triethylamine and water, heated at 100°C for 5 h, filtered, the residue was washed with sodium carbonate solution, and dried at 130°C to obtain modified carbon; (2) dissolving palladium chloride in anhydrous ethanol to form a palladium alcohol solution, adding the modified carbon obtained in step (1) to the palladium alcohol solution, ultrasonicating at 50 kHz for 1-2 h, filtering with suction, washing the filter cake with distilled water and drying at 110° C. to obtain a palladium-carbon catalyst.
3. The method for preparing a carbapenem antibiotic according to claim 2, characterized in that: In step S1, the dosage ratio of raw material 1, anhydrous tetrahydrofuran, CDI, raw material 2 and hydrochloric acid is 1 mmol:4 mL:1.2 mmol:1.2 mmol:2 mL; in the acetone solution of raw material 2, the dosage ratio of raw material 2 to acetone is 1 mmol:1 mL; and the volume ratio of acetonitrile to cyclohexane in the acetonitrile-cyclohexane mixed solution is 1:
1.
4. The method for preparing a carbapenem antibiotic according to claim 3, characterized in that: In step S2, the amount ratio of the intermediate (I) to dichloromethane in the dichloromethane solution of the intermediate (I) is 1 mmol:2 mL; the volume ratio of triethylamine to the dichloromethane solution of the intermediate (I) is 1:8; the amount ratio of (Boc)2O to dichloromethane in the dichloromethane solution of (Boc)2O is 1 g:5 mL; the volume ratio of the dichloromethane solution of (Boc)2O to triethylamine is 10:1; the volume ratio of distilled water to triethylamine is 10:1; the volume ratio of hydrochloric acid to triethylamine is 20:1; the volume ratio of acetonitrile to acetone in the mixed solution of acetonitrile and acetone is 1:
1.
5. The method for preparing a carbapenem antibiotic according to claim 4, characterized in that: In step S3, the amount ratio of raw material 3 to acetonitrile in the acetonitrile solution of raw material 3 is 1 mmol:5 mL; the amount ratio of diisopropylethylamine, intermediate (II) and acetonitrile in the acetonitrile solution of diisopropylethylamine and intermediate (II) is 8 mL:31 mmol:92 mL; the volume ratio of the acetonitrile solution of diisopropylethylamine and intermediate (II) to the acetonitrile solution of raw material 3 is 1:1.5; the volume ratio of ethyl acetate to the acetonitrile solution of raw material 3 is 8:
3.
6. The method for preparing a carbapenem antibiotic according to claim 5, characterized in that: The dosage ratio of deionized water and intermediate III in step S4 is 40 L:1 kg; the mass ratio of 2,6-lutidine, palladium carbon catalyst and intermediate III is 0.5:0.5:1; and the volume ratio of acetone to filtrate is 4:
1.
7. The method for preparing a carbapenem antibiotic according to claim 6, characterized in that: The amount ratio of activated carbon, glycine, triethylamine and water in step (1) is 0.1 g:0.4 mmol:0.2 g:20 g.
8. The method for preparing a carbapenem antibiotic according to claim 7, characterized in that: In step (2), the ratio of palladium chloride to anhydrous ethanol is 20 g:1 L; the ratio of palladium alcohol solution to modified carbon is 15 mL:1 g.
